A Generalized Overview of the Possible Pharmacotherapy and Treatments against SARS-CoV-2
Full Text (PDF)
Syed Sajidul Islam 1 * , Sayka Alam 1, Tiluttoma Khan Rajib 1, Nasrin Akhter 2, Md. Zahidul Islam 1
More Detail
1 Department of Biotechnology and Genetic Engineering, Faculty of Biological Sciences, Jahangirnagar University, Savar, Dhaka-1342, BANGLADESH
2 Department of Biomedical Engineering, Khulna University of Engineering & Technology, Khulna-9203, BANGLADESH
* Corresponding Author

Abstract

A highly pathogenic viral infection with several symptoms have been reported such as fever, cough, breathing difficulty, fatigue, headache, failure of taste or smell sensation, sore throat, congestion and diarrhoea in December, 2019 in Wuhan, China. In 30th January, 2020 World Health Organization (WHO) declared the outbreak of coronavirus disease to be a Public Health Emergency of global Concern. This virus is highly contagious and can be transmitted after close contact with an infected patient, and has quickly spread globally. In this pandemic, several types of drugs, non-drugs treatment, and their combination are being used to manage the coronavirus disease (COVID-19) affected patients which caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Although none of them are officially recommended by any national and international committee such as U.S. Food and Drug Administration (USFDA) because the efficacy and the safety aspects of these treatments are still unidentified and extensively investigated. Different types of potential pharmacotherapy and treatments such as antimalarial, antiviral, antibiotics and many more are presently undertaking clinical-trials to prove their effectiveness in COVID-19 and some of them also showing promising results. This narrative review article summarizes some potential drugs used for the symptoms of coronavirus disease such as antivirals, antibiotics, antimalarial, anti-inflammatory and possible treatments such as neutralizing antibodies from convalescent plasma, umbilical cord mesenchymal stem cells (UC-MSCs) against SARS-CoV-2.

Keywords

License

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Article Type: Review Article

https://doi.org/10.30935/jconseph/9367

J CONT STUDIES EPIDE PUBL HEALTH, 2021 - Volume 2 Issue 1, Article No: ep21001

Publication date: 04 Jan 2021

Article Views: 780

Article Downloads: 393

Open Access References How to cite this article